ERR2278859
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.530
- INTERFERON_GAMMA_RESPONSE+0.530
- MYC_TARGETS_V1+0.480
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.330
- DNA_REPAIR+0.310
- PI3K_AKT_MTOR_SIGNALING+0.270
- HEDGEHOG_SIGNALING+0.260
Top 10 suppressed
- UV_RESPONSE_DN-0.330
- MYOGENESIS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- NOTCH_SIGNALING-0.310
- BILE_ACID_METABOLISM-0.260
- PEROXISOME-0.210
- CHOLESTEROL_HOMEOSTASIS-0.190
- ANGIOGENESIS-0.170
- TNFA_SIGNALING_VIA_NFKB-0.160
- KRAS_SIGNALING_UP-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278873 | — | — | 0.975 |
| 2 | SRR15069615 | — | — | 0.828 |
| 3 | TCGA-K4-A4AC-01A-21R-A26T-07 | — | — | 0.828 |
| 4 | TCGA-CN-A499-01A-11R-A24H-07 | — | — | 0.822 |
| 5 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.822 |
| 6 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.819 |
| 7 | c2d0d36b-83b0-4a2b-a5d7-6567bf5aa557 | — | — | 0.819 |
| 8 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.817 |
| 9 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.810 |
| 10 | MNG921 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |